None listed
Conditions
Interventions
Biological/Vaccine, Non-Stem Cell : One vial (0.65ml) of Zostavax, Varicella-Zoster Virus Vaccine Live (OKA/MERCK), will be injected subcutaneously
Sponsors
Seoul National University Bundang Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adults 65 years of age and older. Have given written informed consent prior to enrollment.
Exclusion criteria
Exclusion criteria: No history of herpes zoster within 5 years, no current history of immune suppression (e.g. malignancy or neoplastic disease, corticosteroid therapy). No immunosuppression resulting from disease (e.g. malignancy, HIV infection), corticosteroids (except intermittent topical or inhaled corticosteroid = greater than 800mcg/day beclomethasone dipropionate or equivalent) or other immunosuppressive/cytotoxic therapy (cancer chemotherapy or organ transplantation). No active neoplastic disease (except local skin cancer or prostate cancer that are stable in the absence of immunosuppressive/cytotoxic therapy). No prior receipt of varicella vaccine. No allergic sensitivity to neomycin. No history of anaphylactoid reaction to gelatin. No significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 6 months). No receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products) or scheduled within 6 weeks after study vaccination. No currently receiving antiviral therapy. No intercurrent illness (e.g. urinary tract infection, influenza) that might interfere with the interpretation of the study. No subjects unlikely to adhere to protocol follow-up. No subjects involved in a conflicting (vaccine) clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference of immunogenicity will be compared according to the frailty status. | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference of antibody response according to the age group will be assessed.;Difference of immunogenicity will be compared according to the baseline cytokine level. | — |
Countries
Korea, Republic of
Contacts
Public ContactJung-Yeon Choi
Seoul National University Bundang Hospital
Outcome results
None listed